Abstract
Summary: Desmoid tumors are a locally invasive neoplasm that can exhibit unpredictable clinical behavior. Although treatment options are numerous, few are supported by level 1 evidence. A recent phase III trial evaluated the efficacy of long-used pegylated liposomal doxorubicin in patients with progressive desmoid tumors. See related article by Xu et al., p. 2198